Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 20/20 | 0.83 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.66 |
| ▸ | PTGFR | P43088 | 1/20 | 0.66 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.66 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.66 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1735898 | 0.98 | PTGER4 (0.85) | PTGER4TBXA2RPTGFRPTGER3PTGER2 | |
| SCHEMBL5223597 | 0.91 | PTGER4 (1.00) | PTGER4 | |
| SCHEMBL1735816 | 0.89 | PTGER4 (1.00) | PTGER4TBXA2RPTGFRPTGER3PTGER2 | |
| SCHEMBL1735894 | 0.86 | PTGER4 (1.00) | PTGER4TBXA2RPTGFRPTGER3PTGER2 | |
| SCHEMBL1734974 | 0.86 | PTGER4 (0.71) | PTGER4TBXA2RPTGFRPTGER3PTGER2 | |
| SCHEMBL5221211 | 0.85 | PTGER4 (0.87) | PTGER4TBXA2RPTGFRPTGER3PTGER2 | |
| SCHEMBL1734977 | 0.84 | PTGER4 (1.00) | PTGER4TBXA2RPTGFRPTGER3PTGER2 | |
| SCHEMBL1734997 | 0.82 | PTGER4 (1.00) | PTGER4TBXA2RPTGFRPTGER3PTGER2 | |
| SCHEMBL5222381 | 0.82 | PTGER4 (1.00) | PTGER4TBXA2RPTGFRPTGER3PTGER2 | |
| SCHEMBL1735045 | 0.82 | PTGER4 (1.00) | PTGER4TBXA2RPTGFRPTGER3PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1885722-B1 | QUINOLINE DERIVATIVES AS EP4 ANTAGONISTS | MERCK CANADA INC (CA) | 2011-11-16 | — | — | EP | claimed |
| US-20110262430-A1 | NOVEL ANTIBODIES | ELLIS JONATHAN HENRY | 2011-10-27 | — | — | US | claimed |
| US-8013159-B2 | Quinoline derivatives as EP4 antagonists | MERCK CANADA INC. (CA) | 2011-09-06 | — | — | US | claimed |
| US-20090099226-A1 | Quinoline derivatives as ep4 antagonists | MERCK CANADA INC. (CA) | 2009-04-16 | — | — | US | claimed |
| EP-1885722-A1 | QUINOLINE DERIVATIVES AS EP4 ANTAGONISTS | Merck Frosst Canada Ltd. (CA) | 2008-02-13 | — | — | EP | claimed |
| WO-2006122403-A1 | QUINOLINE DERIVATIVES AS EP4 ANTAGONISTS | MERCK FROSST CANADA LTD. (CA) | 2006-11-23 | — | — | WO | claimed |
| EP-1885722-B1 | QUINOLINE DERIVATIVES AS EP4 ANTAGONISTS | MERCK CANADA INC (CA) | 2011-11-16 | — | — | EP | disclosed |
| EP-1885722-B1 | QUINOLINE DERIVATIVES AS EP4 ANTAGONISTS | MERCK CANADA INC (CA) | 2011-11-16 | — | — | EP | disclosed |
| US-20110262430-A1 | NOVEL ANTIBODIES | ELLIS JONATHAN HENRY | 2011-10-27 | — | — | US | disclosed |
| US-8013159-B2 | Quinoline derivatives as EP4 antagonists | MERCK CANADA INC. (CA) | 2011-09-06 | — | — | US | disclosed |
| US-8013159-B2 | Quinoline derivatives as EP4 antagonists | MERCK CANADA INC. (CA) | 2011-09-06 | — | — | US | disclosed |
| US-8013159-B2 | Quinoline derivatives as EP4 antagonists | MERCK CANADA INC. (CA) | 2011-09-06 | — | — | US | disclosed |
| US-20090099226-A1 | Quinoline derivatives as ep4 antagonists | MERCK CANADA INC. (CA) | 2009-04-16 | — | — | US | disclosed |
| US-20090099226-A1 | Quinoline derivatives as ep4 antagonists | MERCK CANADA INC. (CA) | 2009-04-16 | — | — | US | disclosed |
| US-20090099226-A1 | Quinoline derivatives as ep4 antagonists | MERCK CANADA INC. (CA) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099226-A1 | Quinoline derivatives as ep4 antagonists | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885TBXA2R 9/4885PTGFR 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.